GlaxoSmithKline and iTeos Therapeutics to co-develop and co-commercialise the treatment for patients with cancer .
The Chief Scientific Officer and President R&D, GSK, Dr Hal Barron, said:
“Immuno-oncology has transformed cancer care but unfortunately less than 30 percent of patients respond to treatment with the current leading immune checkpoint inhibitors.
“Based on the underlying science, we believe that combinations of a PD-1, TIGIT, CD96 and PVRIG inhibitor could become transformative medicines for many patients with cancer. We are excited to collaborate with the team at iTeos and together we can play a leading role in the next generation of immuno-oncology therapies.”
GSK and iTeos Therapeutics will share responsibility and costs for the global development of EOS-448 and will split profits equally in US.
The company GSK will receive an exclusive licence for commercialisation and iTeos Therapeutics will receive royalty payments.
About GSK
It is a multinational pharmaceutical company established in the year 2000 in England by
a merger of Glaxo Wellcome and SmithKline Beecham, it is the tenth largest pharmaceutical
company in the world.
About iTeos Therapeutics
It is a biopharmaceutical company which is trying to discover and develop highly differentiated immuno-oncology therapeutics for patients.
About EOS-448
EOS-448 is an anti-TIGIT human immunoglobulin G1, or IgG1, antibody that we are developing to inhibit the immunosuppressive activity of TIGIT. TIGIT is a cell surface receptor expressed on multiple immune cells, including CD8+ T cells, natural killer, or NK, cells and T regulatory cells,
